Using N-acetylcysteine plus simethicone before upper endoscopy to improve mucosal visibility
Official title: Randomized Controlled Trial to Evaluate the Effect of Premedication With N-acetylcysteine and Simethicone on Mucosal Visibility During Elective Upper Gastrointestinal Endoscopy Using the TUGS Score
Run by Hospital General de Mexicali · NCT07245095 · Data updated 2026-11-12
This trial will test whether taking N-acetylcysteine and simethicone by mouth shortly before an upper endoscopy helps doctors see the lining of the esophagus, stomach, and duodenum better in adults without active GI bleeding.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 132 (estimated) |
| Sponsor | Hospital General de Mexicali Academic / other |
| Locations | 2 sites (Mexicali, Estado de Baja California and 1 other locations) |
| Status | Recruiting |
| Started | September 12, 2025 |
| Main results expected | November 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | November 24, 2025 |
| Trial ID | NCT07245095 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to 70 scheduled for elective diagnostic upper endoscopy who are not actively bleeding and who have no known hypersensitivity to N-acetylcysteine or simethicone.
✕Probably not a fit
People with active gastrointestinal bleeding, prior gastric/bariatric surgery, known motility disorders, pregnant or breastfeeding individuals, or those allergic to the study drugs are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, placebo-controlled multicenter trial comparing a single oral dose of N-acetylcysteine (600 mg) plus simethicone (100 mg) versus placebo (water) given 20–60 minutes before elective diagnostic upper endoscopy. Trained endoscopists blinded to treatment allocation will score mucosal cleanliness using the Toronto Upper Gastrointestinal Cleanliness Score (TUGS). Secondary measures include recording significant endoscopic findings, histopathology results, and any adverse events to evaluate tolerability and safety. Variables such as age, sex, BMI, fasting time, site, and endoscope model will be recorded and controlled for in analysis.
Why it matters
Potential benefit: If successful, this simple premedication could make the mucosa clearer during endoscopy, improving lesion detection and potentially reducing the need for repeat procedures.
How similar studies have gone: Previous trials using simethicone with or without mucolytic agents have generally shown improved mucosal visibility, so the combined NAC-plus-simethicone approach has supportive prior evidence though practices vary by center.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women aged 18 to 70 years old. * Patients who agree to participate in the clinical trial. * Patients without active gastrointestinal bleeding. * Signing of informed consent form. Exclusion Criteria: * Patients with a history of hypersensitivity to N-acetylcysteine * Patients with a history of hypersensitivity to simethicone * Patients with a previous endoscopic diagnosis * Patients with a history of gastric or bariatric surgery * Patients with a history of motor disorders (e.g., scleroderma, diabetic gastroparesis) * Patients taking medications that delay gastric emptying (GLP-1 analogues) * Pregnant or breastfeeding patients * Patients who do not agree to participate in the clinical trial
Where it's running
-
Hospital Almater
Mexicali, Estado de Baja California, Mexico Recruiting -
Hospital General de Mexicali
Mexicali, Estado de Baja California, Mexico Recruiting
Study contacts
- Study coordinator: Luis Andre Sanchez Perez, Resident
- Email: sanchez.luis3@uabc.edu.mx
- Phone: + 52 6863468689
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Morning-strength boost with caffeine or whole-body vibration
This study tests whether taking 300 mg caffeine or using whole-body vibration helps healthy, regularly trained adults see improvements in morning strength and thinking skills.
-
Lactium premedication to see if it prevents emergence agitation after adenotonsillectomy
A preoperative dose of Lactium is tested to see if it prevents emergence agitation in children after adenotonsillectomy.
-
Using virtual reality to reduce the need for preoperative sedative medication
This trial will try virtual reality to see if it reduces the need for sedative premedication in adults who request medication before elective surgery.
-
Oral Premedication Choices to Help Kids Tolerate Venipuncture in Day-Case Surgery
This study tests whether giving oral midazolam alone or with ibuprofen or ketamine helps children ages 4–12 tolerate vein access better during ambulatory procedures.
-
Carminal for H. pylori gastritis
This trial will test if taking 30 ml daily of the Aloe vera–based supplement Carminal together with standard H. pylori therapy helps adults with H. pylori–positive gastritis heal their stomach lining better than standard therapy plus placebo.
-
Exogenous ketone monoester effects on thinking, sensorimotor skills, and driving
This test will try a single dose of a ketone monoester supplement versus a placebo to see if it improves thinking, sensorimotor skills, and driving performance in adults 19–55 who are obese and sedentary, lean and sedentary, or lean and regularly active.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.